Plasma insulin, leptin, adiponectin, resistin, ghrelin, and melatonin in nonalcoholic steatohepatitis patients treated with melatonin

Journal of Pineal Research

Volumn 54, Issue 2, 2013, Pages 154-161

  Gonciarz, MacIej ^a   Bielański, Wladyslaw ^b   Partyka, Robert ^a   Brzozowski, Tomasz ^b   Konturek, Piotr C ^c   Eszyk, Jerzy ^a   Celiński, Krzysztof ^d   Reiter, Russel J ^e   Konturek, Stanislaw J ^b  

^a St Barbara's Main District Hospital   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c Department of Internal Medicine   (Germany)

^d MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^e Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

adiponectin; ghrelin; insulin; melatonin; nonalcoholic steatohepatitis; resistin

Indexed keywords

ADIPONECTIN; AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GHRELIN; INSULIN; LEPTIN; LIVER ENZYME; MELATONIN; RESISTIN;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; MALE; NONALCOHOLIC FATTY LIVER;

ADIPONECTIN; ADULT; FATTY LIVER; FEMALE; GHRELIN; HUMANS; INSULIN; LEPTIN; MALE; MELATONIN; RESISTIN;

EID: 84873428221     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2012.01023.x     Document Type: Article

References (62)

1. Targher G, Day CP, Bonora E,. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350.
2. Bellentani S, Scaglioni F, Marino M, et al., Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 155-161.
3. Dowman JK, Tomlinson JW, Newsome PN,. Pathogenesis of non-alcoholic fatty liver disease. Q J Med 2010; 103: 71-83.
4. Vanni E, Bugianesi E, Kotronen A, et al., From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010; 42: 32-330.
5. Buechler C, Wanninger J, Neumeier M,. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol 2011; 17: 2801-2811.
6. Polyzos SA, Kountouras J, Zavos C, et al., The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2010; 12: 365-383.
7. Marra F, Bertolani C,. Adipokines in liver diseases. Hepatology 2009; 50: 957-969.
8. Shetty S, Kusminski CM, Scherer PE,. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 2009; 30: 234-239.
9. Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ,. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009; doi: 10.1155/2009/831670.
10. Kelesidis T, Kelesidis I, Chou S, et al., Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 2010; 152: 93-100.
11. Mantzoros CS, Magkos F, Brinkoetter M, et al., Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab 2011; 301: E567-E584.
12. Polyzos SA, Kountouras J, Zavos C, et al., The potential adverse role of leptin resistance in nonalcoholic fatty liver disease. A hypothesis based on critical review of the literature. J Clin Gastroenterol 2011; 45: 50-54.
13. Myers MG, Leibel RL, Seeley RJ, et al., Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol Metab 2010; 21: 643-651.
14. Mochado M, Cortes-Pinto H,. Osteopontin: a missing link between hedgehog signaling and fibrosis in nonalcoholic steatohepatitis. Hepatology 2011; 53: 382-384.
15. Angulo P, Alba LM, Petrovic LM, et al., Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004; 41: 943-949.
16. Ukkola O,. Ghrelin and metabolic disorders. Curr Protein Pept Sci 2009; 10: 2-7.
17. Suzuki H, Matsuzaki J, Hibi T,. Ghrelin and oxidative stress in gastrointestinal tract. J Clin Biochem Nutr 2011; 48: 122-125.
18. Yalniz M, Bahcecioglu IH, Ataseven H, et al., Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis. Mediators Inflamm 2006; 6: 34295.
19. Tacke F, Brabant G, Kruck E, et al., Ghrelin in chronic liver disease. J Hepatol 2003; 38: 447-454.
20. Granado M, Martín AI, Lopez-Menduińa M, et al., GH-releasing peptide-2 administration prevents liver inflammatory response in endotoxemia. Am J Physiol Endocrinol Metab 2008; 294: E131-E141.
21. Işeri SÖ, ŞEner G, Saglam B, et al., Ghrelin alleviates biliary obstruction-induced chronic hepatic injury in rats. Regul Pept 2008; 146: 73-79.
22. Marchesini G, Pagotto U, Bugianesi E, et al., Low ghrelin concentrations in nonalcoholic fatty liver disease are related to insulin resistance. J Clin Endocrinol Metab 2003; 88: 5674-5679.
23. Diz-Lois MT, Garcia-Buela J, Suarez F, et al., Altered fasting and postprandial plasma ghrelin levels in patients with liver failure are normalized after liver transplantation. Eur J Endocrinol 2010; 163: 609-616.
24. Singhal W, Lazar M, Ahima R,. Central resistin induces hepatic insulin resistance via neuropeptide Y. J Neurosci 2007; 27: 12924-12932.
25. Bertolani C, Sancho-Bru P, Failli P, et al., Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol 2006; 169: 2042-2053.
26. Bo S, Ciccone G, Durazzo M, et al., Efficacy of antioxidant treatment in reducing resistin serum levels: a randomized study. PLoS Clin Trials 2007; 2: e17.
27. Musso G, Gambino R, Cassader M, et al., A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52: 79-104.
28. Lavine JE, Schwimmer JB, Van Natta ML, et al., Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents. JAMA 2011; 305: 1659-1668.
29. Sanyal A, Chalasani N, Kowdley K, et al., Pioglitazone, vitamin E, placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685.
30. Reiter RJ, Panedes SD, Manchester LC, et al., Reducing oxidative nitrosative stress; a newly discovered gene for melatonin. Crit Rev Biochem Mol Biol 2009; 44: 175-200.
31. Galeno A, Tan DX, Reiter RJ,. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51: 1-16.
32. Stehle JH, Saade A, Rawashed O, et al., A survey of molecular details in the human pineal gland in light of phylogeny, structure, function and chronobiological diseases. J Pineal Res 2011; 51: 17-43.
33. Konturek SJ, Konturek PC, Brzozowski T, et al., Role of melatonin in upper gastrointenstinal tract. J Physiol Pharmacol 2007; 58: 23-52.
34. Barlow-Walden LR, Reiter RJ, Abem M, et al., Melatonin stimulates brain glutathione peroxidase activity. Neurochem Int 1995; 26: 497-502.
35. Rodrigues C, Mayo TC, Sainz RM, et al., Regulation of antioxidant enzymes; a significant role for melatonin. J Pineal Res 2004; 36: 1-9.
36. Gonciarz M, Gonciarz Z, Bielanski W, et al., The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin. J Physiol Pharmacol 2010; 61: 705-710.
37. Gonciarz M, Gonciarz Z, Bielanski W, et al., The effect of long-term treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study. J Physiol Pharmacol 2012; 63: 35-40.
38. Agil A, Rosado I, Ruiz R, et al., Melatonin improves glucose homeostatis in young zucker diabetic fatty rats. J Pineal Res 2012; 52: 203-210.
39. Iqbal N, Seshadri P, Stern L, et al., Serum resistin is not associated with obesity or insulin resistance in humans. Eur Rev Med Pharmacol 2005; 9: 151-165.
40. Ríos-Lugo M, Cano P, Jiménez-Ortega V, et al., Melatonin effect on plasma adiponectin, leptin, insulin, glucose, triglycerides and cholesterol in normal and high fat-fed rat. J Pineal Res 2010; 49: 342-348.
41. Adams L,. Mortality in nonalcoholic fatty liver disease: clues from the Cremona study. Hepatology 2011; 54: 6-8.
42. Peschke E, Schucht H, Mühlbauer E,. Long-term enteral administration of melatonin reduces plasma insulin and increases expression of pineal insulin receptors in both Wistar and type 2-diabetic goto-kakizaki rats. J Pineal Res 2010; 49: 373-381.
43. Peschke E, Hofmann K, Bähr I, et al., The insulin-melatonin antagonism: studies in the LEW.1AR1-iddm rat (an animal model of human mellitus). Diabetologia 2011; 54: 1831-1840.
44. Nogueira TC, Lellis-Santos C, Jesus DS, et al., Absence of melatonin induces night-time hepatic insulin resistance and increased gluconeogenesis due to stimulation of nocturnal unfolded protein response. Endocrinology 2011; 152: 1253-1263.
45. Contreras-Alcantara S, Baba K, Tosini G,. Removal of melatonin receptor type 1 induces insulin resistance in the mouse. Obesity 2010; 18: 1861-1863.
46. Stein LL, Dong MH, Loomba R,. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: current status. Adv Ther 2009; 26: 893-907.
47. Harrison SA,. Thiazolidinedione therapy for nonalcoholic steatohepatitis: go, stop, or proceed with caution? Hepatology 2010; 51: 366-369.
48. Polyzos SA, Toulis KA, Goulis DG, et al., Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Metabol 2011; 60: 313-326.
49. Page ST, Herbst KL, Amory JK, et al., Testosterone administration supresses adiponectin levels in men. J Androl 2005; 26: 85-92.
50. Alonso-Vale MI, Andreotti S, Peres SB, et al., Melatonin enhances leptin expression by rat adipocytes in the presence of insulin. Am J Physiol Endocrinol Metab 2005; 288: E805-E812.
51. Alonso-Vale MI, Peres SB, Vernochet C, et al., Adipocyte differentiation is inhibited by melatonin through the regulation of C/EBPb eta transcriptional activity. J Pineal Res 2009; 47: 221-227.
52. Lee JH, Chan JL, Yiannakouris N, et al., Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003; 88: 4848-4856.
53. Motilva V, Garcia-Murinos S, Talero E, et al., New paradigms in chronic intestinal stimulation and colon cancer; role of melatonin. J Pineal Res 2011; 51: 44-60.
54. Celinski K, Konturek PC, Slomka M, et al., Altered basal and postprandial plasma melatonin, gastrin, ghrelin, leptin and insulin in patients with liver cirrhosis and portal hypertension without and with oral administration of melatonin or tryptophan. I Pineal Res 2009; 46: 408-414.
55. Celinski K, Konturek SJ, Konturek PC, et al., Melatonin or L-tryptophan accelerates healing of gastroduodenal ulcers in patients treated with omeprazole. J Pineal Res 2011; 50: 389-394.
56. Walden-Hanson T, Mitton DR, McCants RL, et al., Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and independent of food intake and total body fat. Endocrinology 2000; 141: 487-497.
57. Plonka M, Konturek PC, Bielanski W, et al., Relationship between ghrelin and Helicobacter pylori infection in polish adult shepherds and their children. Aliment Pharmacol Ther 2007; 24: 160-168.
58. Mustonen A, Nieminen P, Uyvarinen H,. Preliminary evidence that pharmacologic melatonin treatment decreases rat gherkin levels. Endocrine 2001; 1: 43-46.
59. Murad A, Hassan H, Husein H, et al., Serum resistin levels in nonalcoholic fatty liver disease and their relationship to severity of liver disease. JEMDSA 2010; 15: 53-56.
60. Baranova A, Gowder SJ, Schlauch K, et al., Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obesity patients with non-alcoholic fatty liver disease and insulin resistance. Surg Obes 2006; 16: 1118-1125.
61. Hivert MF, Sullivan LM, Fox CS, et al., Associations of adiponectin, resistin, and tumor necrosis factor-α with insulin resistance. J Clin Endocrinol Metab 2008; 93: 3165-3172.
62. Pagano C, Soardo G, Pilon C, et al., Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 2006; 91: 1081-1086.